TY - JOUR
T1 - Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer
AU - Miyata, Hiroshi
AU - Yano, Masahiko
AU - Yasuda, Takushi
AU - Hamano, Rie
AU - Yamasaki, Makoto
AU - Hou, Eihou
AU - Motoori, Masaaki
AU - Shiraishi, Osamu
AU - Tanaka, Koji
AU - Mori, Masaki
AU - Doki, Yuichiro
N1 - Funding Information:
This study is supported in part by a grant from Osaka Foundation for the Prevention of Cancer and Cardiovascular Diseases.
PY - 2012/6
Y1 - 2012/6
N2 - Background & aims: Enteral nutrition (EN) is provided for patients with cancer. However, Little is known about the clinical efficacy of EN support during chemotherapy in patients with cancer. Methods: Ninety-one patients who received neoadjuvant chemotherapy (5-fluorouracil, cisplatin and adriamycin) for esophageal cancer were enrolled to receive either EN (n = 47) or PN (n = 44) at random. The primary endpoint was the incidence of chemotherapy-related toxicities during chemotherapy. Results: Total and dietary intake calories during chemotherapy were equal in the two groups. There were no significant differences in serum albumin level and body weight change after chemotherapy between the two groups. There was no significant difference in tumor response to chemotherapy between the two groups (EN: 51%, PN: 55%, p = 0.886). Leukopenia and neutropenia of grade 3 or 4, defined according to the Common Toxicities Criteria of the National Cancer Institute, were significantly less frequent in the EN group than PN group (leukopenia: 17% vs 41%, p = 0.011, neutropenia: 36% vs 66%, p = 0.005). Lymphopenia and thrombocytopenia tended to be less frequent in the EN group, albeit insignificantly. Conclusions: Compared with PN support, EN support during neoadjuvant chemotherapy reduced the incidence of chemotherapy-related hematological toxicities in patients with esophageal cancers. The clinical trial registration number: UMIN000004483.
AB - Background & aims: Enteral nutrition (EN) is provided for patients with cancer. However, Little is known about the clinical efficacy of EN support during chemotherapy in patients with cancer. Methods: Ninety-one patients who received neoadjuvant chemotherapy (5-fluorouracil, cisplatin and adriamycin) for esophageal cancer were enrolled to receive either EN (n = 47) or PN (n = 44) at random. The primary endpoint was the incidence of chemotherapy-related toxicities during chemotherapy. Results: Total and dietary intake calories during chemotherapy were equal in the two groups. There were no significant differences in serum albumin level and body weight change after chemotherapy between the two groups. There was no significant difference in tumor response to chemotherapy between the two groups (EN: 51%, PN: 55%, p = 0.886). Leukopenia and neutropenia of grade 3 or 4, defined according to the Common Toxicities Criteria of the National Cancer Institute, were significantly less frequent in the EN group than PN group (leukopenia: 17% vs 41%, p = 0.011, neutropenia: 36% vs 66%, p = 0.005). Lymphopenia and thrombocytopenia tended to be less frequent in the EN group, albeit insignificantly. Conclusions: Compared with PN support, EN support during neoadjuvant chemotherapy reduced the incidence of chemotherapy-related hematological toxicities in patients with esophageal cancers. The clinical trial registration number: UMIN000004483.
UR - http://www.scopus.com/inward/record.url?scp=84861345919&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84861345919&partnerID=8YFLogxK
U2 - 10.1016/j.clnu.2011.11.002
DO - 10.1016/j.clnu.2011.11.002
M3 - Article
C2 - 22169459
AN - SCOPUS:84861345919
SN - 0261-5614
VL - 31
SP - 330
EP - 336
JO - Clinical Nutrition
JF - Clinical Nutrition
IS - 3
ER -
